Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

Clinical trial NCT06722599 · RECRUITING

Trial details

NCT number: NCT06722599
Sponsor: Shu Wang
Status: RECRUITING
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2019-01-01
Primary completion: 2028-12-31
Enrollment: 171

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.